Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2025—Tasso, a provider of clinical-grade blood collection solutions, and ARUP Laboratories announced they have entered into a partnership to develop and operationalize high-quality, at-home blood testing services to support clinical research.
March 2025—The BD board of directors authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD. The company says the aim is to enhance strategic focus and growth-oriented investments and capital allocation for BD and the separated business and to enhance value creation for shareholders. The decision was the result of a business portfolio evaluation, launched by BD in early 2024.
March 2025—Roche announced that its Elecsys sFlt-1/PlGF ratio for preeclampsia has received FDA 510(k) clearance. The preeclampsia ratio supports the management of pregnant patients who have a singleton pregnancy and is intended to help clinicians stratify hospitalized patients into low- and high-risk categories for developing severe preeclampsia within two weeks of presentation.
March 2025—Roche announced that its Elecsys sFlt-1/PlGF ratio for preeclampsia has received FDA 510(k) clearance. The preeclampsia ratio supports the management of pregnant patients who have a singleton pregnancy and is intended to help clinicians stratify hospitalized patients into low- and high-risk categories for developing severe preeclampsia within two weeks of presentation.
February 2025—StatLab Medical Products announced it has reached an agreement to acquire Diapath (Martinengo, Italy), a manufacturer of histology and cytology products and equipment. The integration of Diapath, with its equipment offerings, manufacturing capabilities, and established customer base across Europe, Asia-Pacific, the Middle East, Africa, and Latin America positions StatLab to expand its market access, according to a StatLab press statement.
February 2025—Qiagen announced that the FDA has cleared its QIAstat-Dx meningitis/encephalitis panel for clinical use. The panel simultaneously analyzes several of the most common viral, bacterial, and fungal pathogens responsible for community-acquired meningitis/encephalitis.
February 2025—Mainz Biomed announced an agreement with Quest Diagnostics to support commercialization of Mainz Biomed’s next-generation screening test for colorectal cancer, ColoAlert. Quest will provide clinical trial laboratory services for Mainz Biomed’s ReconAAsense study, a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States to develop data supporting FDA validation of the test. Mainz Biomed will provide Quest with the option to exercise semi-exclusive rights to provide testing services based on the test kit for an 18-month period, assuming the test’s approval by the FDA.
February 2025—Werfen announced FDA 510(k) clearance for the Aptiva antiphospholipid syndrome immunoglobulin G and immunoglobulin M reagents. These immunoassay reagents use Aptiva’s particle-based multianalyte technology for the semiquantitative determination of anticardiolipin and anti-beta 2 glycoprotein 1 IgG and IgM in human serum and aid in diagnosing primary and secondary APS, when used in conjunction with other laboratory and clinical findings.
February 2025—Verichem Laboratories has announced the availability of multilevel clinical reference materials intended for the calibration and calibration verification of acetaminophen and salicylate assays on a wide array of diagnostic testing systems. The materials come in a ready-to-use, liquid-stable format that incorporates the serum-like reactivity of a protein-based matrix with the gravimetric accuracy of an absolute standard. The kit contains 5.0 mL of material at six concentration levels and has a shelf life of 18 months when stored at 2° to 8°C. The product also contains ethanol and lactate to determine the calibration verification of these assays.
February 2025—Beckman Coulter Diagnostics announced the FDA has granted breakthrough device designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio. The blood test measures the ratio of phosphorylated tau protein (pTau217) to beta‑amyloid 1-42, two key biomarkers implicated in the neurodegenerative processes of Alzheimer’s disease. A blood-based IVD test that can quantify these biomarkers in plasma could provide a noninvasive, accessible, and earlier method of detecting Alzheimer’s-related pathology, potentially before clinical symptoms manifest, the company said in a statement.
